By Matthew Carr There are few sectors more exciting than biotech.
The companies within it are pioneering breakthroughs and innovations. But that’s not all.
Because these trailblazers are potentially revolutionizing new treatments or curing diseases, their shares are extremely volatile.
They can skyrocket on promising data and deals…
And tumble back to Earth just as quickly on bad results.
That’s why, today, we’re looking at overbought biotech stocks that may be flying too close to the sun.
Investors don’t need to dig deep to find evidence of this.
Just look at the recent rise and fall of NextCure (Nasdaq: NXTC)…
Shares blasted off a staggering 248.9%!
That was just a one-day gain! …read more